AVP and ductal breast carcinoma in situ: DeCensi and Lazzeroni et al.44,45 have shown in recent results from the Tam01study that low dose tamoxifen of 5mg taken daily for 3 years in ADH (atypical ductalhyperplasia), LCIS (Lobular carcinoma in situ) and DCIS patients reduced breast cancersecond events by 50% with limited side-effects.